Skip to main content

Table 2 Sample’s characteristics, according to the presence of no DM or prediabetes, accessed by HbA1c

From: Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test – which method to choose for the diagnosis?

  HbA1c P value
<5.7% 5.7–6.4%
n (%) 189 (85.9) 31 (14.1)  
Sex [n (%)]    0.623
 Male 116 (61.4) 17 (54.8)  
 Female 73 (38.6) 14 (45.2)  
Age [years, mean (SD)] 45 (11.3) 50.4 (11.9) 0.016
Duration of HIV infection [years, median (IR)] 8 (6) 8 (7.0) 0.698
cART [years, median (IR)] 6 (6.5) 7 (7.0) 0.136
Clinical lipodystrophy [n (%)]    0.909
 Without CL 91 (48.1) 14 (45.2)  
 With CL 98 (51.9) 17 (54.8)  
Body Composition [n (%)]    0.469
 No lipodystrophy 28 (15.3) 3 (10)  
 Isolated central fat accumulation 59 (32.2) 10 (33.3)  
 Lipoatrophy 52 (28.4) 6 (20)  
 Mixed form of lipodystrophy 44 (24) 11 (36.7)  
BMI [(kg/m2), mean (SD)] 25 (4.5) 26.9 (4.5) 0.031
Waist circumference [cm, mean (SD)] 90.9 (11.6) 95.2 (13.2) 0.065
CD4 cell count [cells/mm3, median (IR)] 500 (345) 528 (312) 0.819
HIV RNA (<50) [n (%)] 165 (100) 27 (100)  
Hepatitis C co-infection [n (%)] 57 (30.8) 7 (22.6) 0.474
CDC clinical categories [n (%)]    0.093
 A 107 (56.6) 12 (38.7)  
 B 5 (2.6) 0 (0)  
 C 77 (40.7) 19 (61.3)  
ART [n (%)]    
 IP 106 (56.1) 17 (54.8) 0.999
 NNRTI 88 (46.6) 14 (45.2) 0.999
 NRTI 182 (96.3) 28 (90.3) 0.152
HOMA-IR index [median (IR)] 1.6 (1.5) 2.5 (5.1) 0.023
QUICKI index [median (IR)] 0.4 (0.1) 0.3 (0.1) 0.023
Total cholesterol [mg/dL, mean (SD)] 225.6 (55.4) 219 (55.8) 0.544
LDL- cholesterol [mg/dL, mean (SD)] 133.5 (47.5) 140.2 (44.6) 0.473
HDL- cholesterol [mg/dL, mean (SD)] 48.3 (14.4) 45.8 (11.8) 0.374
Triglycerides [mg/dL, median (IR)] 203 (198) 139 (133.8) 0.010
Statin use [n (%)] 41 (21.7) 5 (16.1) 0.640
Fibrate use [n (%)] 61 (32.3) 4 (12.9) 0.048
  1. DM diabetes mellitus, HbA1c glycated haemoglobin, CL clinical lipodystrophy, cART combination antiretroviral therapy, BMI body mass index, ART antiretroviral therapy, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, HOMA homeostatic model assessment index, QUICKI quantitative insulin sensitivity check index, SD standard deviation, IR interquartile range